Maureen Oconnell
CIK 1111318 · EVP, CAO & CFO · last filed 2026-09-04
Maureen Oconnell is an EVP, CAO & CFO who has filed 97 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing shows the insider sold $152.0K of ACTG on Sep 4, 2026. Across all open-market trades the lifetime net is −$20.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $4.8M across reported positions. 15 SEC filings were submitted jointly with ACACIA RESEARCH CORP.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
SCHL price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ACTG | Director | 254,655 | $4.17 | $1.06M | -$103.6K | 12 | 2026-09-04 |
| TEX | Director | 16,351 | $50.76 | $830.0K | $0 | 2 | 2026-03-09 |
| REV Group, Inc. (REVG) Delisted | Director | 2,105 | $63.90 | $134.5K | $0 | 5 | 2026-02-02 |
| HHS | Director | 25,414 | $4.36 | $110.8K | $0 | 3 | 2020-09-02 |
| Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Director | 0 | — | — | $0 | 6 | 2018-02-13 |
| SCHL | EVP, CAO & CFO | 71,771 | $39.48 | $2.83M | -$19.86M | 68 | 2017-09-26 |
Recent Filings
97 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-04 | ACTG | Sell (S) | −33,000 | -$152.0K | EDGAR |
| 2026-08-20 | ACTG | Sell (S) | −10,000 | -$46.0K | EDGAR |
| 2026-08-19 | ACTG | Notice (144) | −10,000 | -$45.0K | EDGAR |
| 2026-06-25 | ACTG | Grant (A) | +25,052 | $0 | EDGAR |
| 2026-03-09 | TEX | Grant (A) | +794 | $52.6K | EDGAR |
| 2026-02-04 | TEX | Grant (A) | +15,557 | $0 | EDGAR |
| 2026-02-02 | REV Group, Inc. (REVG) Delisted | Disp (D) | −15,539 | $0 | EDGAR |
| 2025-12-05 | REV Group, Inc. (REVG) Delisted | Grant (A) | +2,105 | $0 | EDGAR |
| 2025-06-03 | ACTG | Grant (A) | +32,172 | $0 | EDGAR |
| 2024-12-10 | REV Group, Inc. (REVG) Delisted | Grant (A) | +3,611 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.